Author/Authors :
Shamsara، Jamal نويسنده , , Behravan، Javad نويسنده , , Falsoleiman، Homa نويسنده , , Mohammadpour، Amir Hooshang نويسنده PhD, Pharmaceutical Research Center, Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran , , Ramezani، Mohammad نويسنده PhD, Pharmaceutical Research Center, Nanotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran ,
Abstract :
BACKGROUND: Pentoxifylline has anti-inflammatory properties and could suppress some
inflammatory processes including tumor necrosis factor-alpha (TNF-?) production. We assessed
the effects of a two-month administration of pentoxifylline on nuclear factor-kappa B (NF?B)
pathways in patients with coronary artery disease (CAD) in which inflammatory pathways,
especially NF?B transcription factors, have a critical role.
METHODS: A double-blind randomized placebo-controlled study design was used. Forty CAD
patients were randomized to either 2 months of pentoxifylline treatment (1200 mg/day) (n = 20)
or placebo treatment (n = 20). Blood samples were obtained just before and after two months of
treatment. P50 protein concentration in peripheral blood mononuclear cells (PBMCs) was
measured by Enzyme Linked ImmunoSorbent Assay (ELISA) method.
RESULTS: P50 concentration did not significantly change during two months of pentoxifylline
administration.
CONCLUSION: Longer pentoxifylline administration is needed to see its favorable effects on
NF?B family elements.
